A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Conditions de participation

• Sexe:

  ALL

• Âges admissibles:

  18 and up

Critères de participation

Inclusion Criteria:

* Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,
* Stable clinical status as deemed by responsible investigator,
* Personally (or caregiver) willing and deemed capable to self-administer with teaching,
* Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment,
* Signed informed consent.

Exclusion Criteria:

* Currently participating in clinical trials that includes the use of bortezomib,
* History of allergic reactions to bortezomib,
* History of bleeding attributable to bortezomib,
* History of greater than or equal to grade 3 side effects attributable to bortezomib,
* Clinically deemed unlikely to be compliant with therapy by responsible investigator,
* Life expectancy anticipated to be less than 6 months,
* Deemed geographically inaccessible to receive care.